These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 1741813)

  • 1. Sustained plasma concentrations of fluoxetine and/or norfluoxetine four and eight weeks after fluoxetine discontinuation.
    Pato MT; Murphy DL; DeVane CL
    J Clin Psychopharmacol; 1991 Jun; 11(3):224-5. PubMed ID: 1741813
    [No Abstract]   [Full Text] [Related]  

  • 2. Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder?
    Koran LM; Cain JW; Dominguez RA; Rush AJ; Thiemann S
    Am J Psychiatry; 1996 Nov; 153(11):1450-4. PubMed ID: 8890679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accumulation of fluoxetine and norfluoxetine in human brain during therapeutic administration.
    Renshaw PF; Guimaraes AR; Fava M; Rosenbaum JF; Pearlman JD; Flood JG; Puopolo PR; Clancy K; Gonzalez RG
    Am J Psychiatry; 1992 Nov; 149(11):1592-4. PubMed ID: 1415832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study.
    Amsterdam JD; Fawcett J; Quitkin FM; Reimherr FW; Rosenbaum JF; Michelson D; Hornig-Rohan M; Beasley CM
    Am J Psychiatry; 1997 Jul; 154(7):963-9. PubMed ID: 9210747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between antidepressant response and plasma concentrations of fluoxetine and norfluoxetine.
    Norman TR; Gupta RK; Burrows GD; Parker G; Judd FK
    Int Clin Psychopharmacol; 1993; 8(1):25-9. PubMed ID: 8473717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of long-term fluoxetine treatment of obsessive-compulsive disorder.
    Frenkel A; Rosenthal J; Nezu A; Winston A
    Mt Sinai J Med; 1990 Nov; 57(6):348-52. PubMed ID: 2079952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ratio of plasma fluoxetine to norfluoxetine concentrations and associated sedation.
    Keck PE; McElroy SL
    J Clin Psychiatry; 1992 Apr; 53(4):127-9. PubMed ID: 1564047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluoxetine and norfluoxetine plasma concentrations during relapse-prevention treatment.
    Brunswick DJ; Amsterdam JD; Fawcett J; Quitkin FM; Reimherr FW; Rosenbaum JF; Beasley CM
    J Affect Disord; 2002 Apr; 68(2-3):243-9. PubMed ID: 12063152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Red cell and plasma concentrations of fluoxetine and norfluoxetine.
    Amitai Y; Kennedy E; DeSandre P; Fawcett J; Frischer H
    Vet Hum Toxicol; 1993 Apr; 35(2):134-6. PubMed ID: 8470355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioral and biological results.
    Pigott TA; Pato MT; Bernstein SE; Grover GN; Hill JL; Tolliver TJ; Murphy DL
    Arch Gen Psychiatry; 1990 Oct; 47(10):926-32. PubMed ID: 2222131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum fluoxetine and norfluoxetine concentrations and antidepressant response.
    Kelly MW; Perry PJ; Holstad SG; Garvey MJ
    Ther Drug Monit; 1989; 11(2):165-70. PubMed ID: 2785723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluoxetine and norfluoxetine plasma levels after discontinuing fluoxetine therapy.
    Brunswick DJ; Amsterdam JD; Fawcett J; Quitkin FM; Reimherr FW; Rosenbaum JF; Beasley CM
    J Clin Psychopharmacol; 2001 Dec; 21(6):616-8. PubMed ID: 11763012
    [No Abstract]   [Full Text] [Related]  

  • 13. Fluoxetine and norfluoxetine plasma levels after treatment discontinuation in man.
    Vandel S; Bertschy G; Bouquet S; Bonin B; Vittouris N
    Therapie; 1994; 49(2):141-2. PubMed ID: 7817338
    [No Abstract]   [Full Text] [Related]  

  • 14. Plasma concentrations of the enantiomers of fluoxetine and norfluoxetine: sources of variability and preliminary observations on relations with clinical response.
    Jannuzzi G; Gatti G; Magni P; Spina E; Pacifici R; Zuccaro P; Torta R; Guarneri L; Perucca E
    Ther Drug Monit; 2002 Oct; 24(5):616-27. PubMed ID: 12352933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast-feeding.
    Kim J; Riggs KW; Misri S; Kent N; Oberlander TF; Grunau RE; Fitzgerald C; Rurak DW
    Br J Clin Pharmacol; 2006 Feb; 61(2):155-63. PubMed ID: 16433870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluoxetine treatment of obsessive-compulsive disorder: an open clinical trial.
    Liebowitz MR; Hollander E; Schneier F; Campeas R; Hatterer J; Papp L; Fairbanks J; Sandberg D; Davies S; Stein M
    J Clin Psychopharmacol; 1989 Dec; 9(6):423-7. PubMed ID: 2687337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of fluoxetine and norfluoxetine by high-performance liquid chromatography.
    Wong SH; Dellafera SS; Fernandes R; Kranzler H
    J Chromatogr; 1990 Jan; 499():601-8. PubMed ID: 2324217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Open trial of fluoxetine in obsessive-compulsive disorder.
    Jenike MA; Buttolph L; Baer L; Ricciardi J; Holland A
    Am J Psychiatry; 1989 Jul; 146(7):909-11. PubMed ID: 2787123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of the antidepressant fluoxetine and its metabolite norfluoxetine in serum by reversed-phase HPLC with ultraviolet detection.
    Orsulak PJ; Kenney JT; Debus JR; Crowley G; Wittman PD
    Clin Chem; 1988 Sep; 34(9):1875-8. PubMed ID: 3262022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluoxetine treatment of obsessive-compulsive disorder.
    Turner SM; Jacob RG; Beidel DC; Himmelhoch J
    J Clin Psychopharmacol; 1985 Aug; 5(4):207-12. PubMed ID: 3894437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.